What do systematic reviews say?

G‐CSF vs placebo

It is very uncertain whether G‐CSF changes overall survival compared with placebo (very low certainty).

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  HR 0.8 [0.44, 1.46]
  1 study · 64 participants
  Very low

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 111 participants
  Very low

G‐CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 167 participants
  Very low

G‐CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low